Dunsire Takes XTuit Helm As First Targets Approach The Clinic
The privately-held biopharma, focused on fibrotic diseases and cancer, appointed oncology veteran Deborah Dunsire as president and CEO as the firm’s first drug candidates mature toward the clinic.
You may also be interested in...
Coming out of stealth with a $22 million Series A round, the biotech thinks its therapies targeting abnormal stroma could improve the activity of checkpoint inhibitors in cancer combo therapy and possibly reverse fibrosis in advanced liver disease.
The ADC specialist could have a fourth cancer drug on the market this year and is preparing for its first commercial launch in Europe.
The virtual J.P. Morgan Healthcare meeting was missing the usual energy but still had substance.